152 related articles for article (PubMed ID: 36332675)
1. Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation.
Tang LWT; Chan ECY
Biochem Pharmacol; 2022 Dec; 206():115336. PubMed ID: 36332675
[TBL] [Abstract][Full Text] [Related]
2. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
Tang LWT; Teng JW; Verma RK; Koh SK; Zhou L; Go ML; Fan H; Chan ECY
Drug Metab Dispos; 2021 Sep; 49(9):856-868. PubMed ID: 34326139
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
Kalgutkar AS; Obach RS; Maurer TS
Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).
Kamel A; Harriman S
Drug Discov Today Technol; 2013; 10(1):e177-89. PubMed ID: 24050247
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
Tang LWT; Verma RK; Fan H; Chan ECY
Mol Pharmacol; 2021 Apr; 99(4):266-276. PubMed ID: 33436520
[TBL] [Abstract][Full Text] [Related]
6. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A.
Tang LWT; Wei W; Verma RK; Koh SK; Zhou L; Fan H; Chan ECY
Drug Metab Dispos; 2022 May; 50(5):529-540. PubMed ID: 35153194
[TBL] [Abstract][Full Text] [Related]
7. Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors.
Jackson KD; Durandis R; Vergne MJ
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103502
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation.
Zhang T; Rao J; Li W; Wang K; Qiu F
Drug Metab Rev; 2020 Nov; 52(4):501-530. PubMed ID: 33043714
[TBL] [Abstract][Full Text] [Related]
9. Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicity.
Paludetto MN; Puisset F; Chatelut E; Arellano C
Med Res Rev; 2019 Nov; 39(6):2105-2152. PubMed ID: 31111528
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.
Tang LWT; Teng JW; Koh SK; Zhou L; Go ML; Chan ECY
Chem Res Toxicol; 2021 Jul; 34(7):1800-1813. PubMed ID: 34189909
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights.
Mirzaei MS; Ivanov MV; Taherpour AA; Mirzaei S
Chem Res Toxicol; 2021 Apr; 34(4):959-987. PubMed ID: 33769041
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.
Foti RS; Dalvie DK
Drug Metab Dispos; 2016 Aug; 44(8):1229-45. PubMed ID: 27298339
[TBL] [Abstract][Full Text] [Related]
13. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
[TBL] [Abstract][Full Text] [Related]
14. Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes.
Hu Y; Yang S; Shilliday FB; Heyde BR; Mandrell KM; Robins RH; Xie J; Reding MT; Lai Y; Thompson DC
Drug Metab Dispos; 2010 Sep; 38(9):1522-31. PubMed ID: 20530221
[TBL] [Abstract][Full Text] [Related]
15. Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry.
Yukinaga H; Takami T; Shioyama SH; Tozuka Z; Masumoto H; Okazaki O; Sudo K
Chem Res Toxicol; 2007 Oct; 20(10):1373-8. PubMed ID: 17867646
[TBL] [Abstract][Full Text] [Related]
16. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
17. Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice.
Yan M; Li W; Li WB; Huang Q; Li J; Cai HL; Gong H; Zhang BK; Wang YK
Drug Metab Rev; 2023; 55(1-2):94-106. PubMed ID: 36453523
[TBL] [Abstract][Full Text] [Related]
18. Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology.
Leow JWH; Tang LWT; Chan ECY
Adv Pharmacol; 2022; 95():131-176. PubMed ID: 35953154
[TBL] [Abstract][Full Text] [Related]
19. Induction via Functional Protein Stabilization of Hepatic Cytochromes P450 upon gp78/Autocrine Motility Factor Receptor (AMFR) Ubiquitin E3-Ligase Genetic Ablation in Mice: Therapeutic and Toxicological Relevance.
Kwon D; Kim SM; Jacob P; Liu Y; Correia MA
Mol Pharmacol; 2019 Nov; 96(5):641-654. PubMed ID: 31492698
[TBL] [Abstract][Full Text] [Related]
20. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
Masubuchi Y; Horie T
Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
